However, control IgG-treated mice showed higher levels of Ki67+ proliferating tumor cells, which were modestly reduced by both paclitaxel and xentuzumab single treatments and significantly reduced by the combination treatment of xentuzumab with paclitaxel (Fig. 5c, d). Here, MKI67 is linked to neoplasm.